Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsEmergency psychiatry

Psych MEQs / SAQs · Emergency psychiatry

Lithium toxicity — acute-on-chronic emergency (MEQ)

FRANZCP-style MEQ on chronic/acute-on-chronic lithium toxicity: interactions, EXTRIP, supportive care, SILENT risk, restart decision.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 62-year-old man with bipolar I disorder has taken lithium carbonate 900 mg at night for 12 years. Baseline troughs were 0.7–0.8 mmol/L. Three weeks ago his GP started ibuprofen for knee pain and increased ramipril. After two days of vomiting and poor oral intake he presents with coarse tremor, ataxia, dysarthria and fluctuating confusion. HR 92, BP 108/70, dry mucous membranes, SpO2 98 percent, temperature 36.9 C. Capillary glucose 5.8 mmol/L. ECG shows T-wave flattening. Serum lithium 2.6 mmol/L; creatinine 180 micromol/L (baseline 95); sodium 133 mmol/L. (i) Classify the toxicity pattern and explain the mechanisms linking his precipitants to the level. (ii) Outline immediate management including investigations and supportive care with named fluid strategy principles. (iii) Apply EXTRIP recommendations to decide on extracorporeal treatment and state preferred modality plus post-treatment monitoring. (iv) Discuss differentials you must not miss. (v) After recovery, outline prevention, monitoring, and the lithium restart decision. (20 marks)

Model answer

Reveal model answer

(i) Pattern and mechanisms. This is chronic or acute-on-chronic lithium toxicity: long-term therapeutic use with reduced clearance plus intercurrent illness, not a single naive overdose. Neurotoxicity dominates (coarse tremor, ataxia, dysarthria, confusion) at 2.6 mmol/L with AKI. Ibuprofen (NSAID) reduces renal prostaglandins and lithium clearance; ramipril (ACE inhibitor) can reduce GFR and promote lithium retention; vomiting/poor intake causes volume depletion, increasing proximal sodium-linked lithium reabsorption. Pattern-of-exposure literature links chronic/acute-on-chronic presentations to greater severity relative to serum numbers.[5][3][4][2]

(ii) Immediate management. Stop lithium, stop NSAID, hold/review ACEI. ABCDE already partly reassuring but continue cardiac monitoring given ECG changes. Investigations: serial lithium levels timed from last dose, U&E/creatinine trend, sodium, calcium/TFT context, glucose already done, consider co-ingestants only if history suggests. Supportive care: IV isotonic saline to restore euvolemia and renal perfusion — cornerstone when volume depleted; avoid forced loop-diuretic diuresis as primary detox; activated charcoal does not bind lithium. Early toxicology and nephrology involvement.[8][2]

(iii) EXTRIP. Lithium is dialyzable. Recommended ECTR if severe poisoning; or impaired kidney function with Li greater than 4.0 mEq/L; or decreased consciousness, seizures, or life-threatening dysrhythmias at any level. Suggested if Li greater than 5.0, significant confusion, or expected time to Li less than 1.0 exceeds 36 hours. This patient has impaired kidney function, significant confusion, and Li 2.6 — he may not yet hit the Li greater than 4.0 recommended band, but significant confusion is a suggested criterion, and expected clearance time with AKI may exceed 36 hours; escalate with nephrology now rather than waiting for coma. Preferred modality: haemodialysis; continuous RRT acceptable alternative. Continue until clinical improvement or Li less than 1.0 (minimum 6 hours if level not measurable). Recheck for rebound after dialysis.[1]

(iv) Differentials. Cerebellar stroke, Wernicke encephalopathy, hyponatraemia-related encephalopathy, other toxidromes (serotonin toxicity, NMS if antipsychotics), seizure-related injury, primary psychiatric decompensation with incidental level rise. Discriminators: lithium history + level + renal precipitants + progressive neuro ladder.[2][8]

(v) After recovery. Document precipitants; sick-day rules; medication reconciliation (avoid unsupervised NSAID/ACEI/thiazide combinations); timed 12-hour trough monitoring and renal–thyroid–calcium schedule if lithium restarts. Restart is a shared decision: lithium’s maintenance and anti-suicide value may still justify supervised reintroduction after renal recovery and education — not automatic same-dose restart into the same drug trap. Counsel on SILENT risk if deficits persist and arrange neurology/rehab early.[7][6][3]

Common errors

  • Treating only the number and ignoring chronic pattern severity
  • Giving activated charcoal as if it binds lithium
  • Missing NSAID + ACEI + dehydration as the interaction triad
  • No EXTRIP discussion despite confusion and AKI
  • Forgetting post-dialysis rebound
  • Nihilistic permanent lithium ban without weighing anti-suicide benefit after precipitant fixed
[1] [3] [8]

Examiner notes

Full marks require pattern naming, interaction mechanisms, supportive saline principles, accurate EXTRIP recommended/suggested criteria with HD preference and rebound, and a nuanced restart plan. Vague “fluids and observe” without EXTRIP language fails at fellowship standard. [1]

References

  1. [1]Decker BS, Goldfarb DS, Dargan PI, et al. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup Clin J Am Soc Nephrol, 2015.PMID 25583292
  2. [2]Baird-Gunning J, Lea-Henry T, Hoegberg LCG, et al. Lithium Poisoning J Intensive Care Med, 2017.PMID 27516079
  3. [3]Finley PR Drug Interactions with Lithium: An Update Clin Pharmacokinet, 2016.PMID 26936045
  4. [4]Finley PR, O'Brien JG, Coleman RW Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction J Clin Psychopharmacol, 1996.PMID 8834421
  5. [5]Waring WS, Laing WJ, Good AM, et al. Pattern of lithium exposure predicts poisoning severity: evaluation of referrals to a regional poisons unit QJM, 2007.PMID 17412747
  6. [6]Adityanjee, Munshi KR, Thampy A The syndrome of irreversible lithium-effectuated neurotoxicity Clin Neuropharmacol, 2005.PMID 15714160
  7. [7]Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ, 2013.PMID 23814104
  8. [8]Waring WS Management of lithium toxicity Toxicol Rev, 2006.PMID 17288494